We have identified two distinct sites where hsa-miR-214-3p exerts similar regulatory effects on B7H3, providing novel insights into the role of hsa-miR-214-3p in B7H3 regulation and laying a robust theoretical foundation for the clinical application of targeting either B7H3 or hsa-miR-214-3p in breast cancer therapies. The gene discussed is CD276; the disease is breast cancer.